Thomas J. Herzfeld Advisors, Inc. Novo Nordisk A S Transaction History

Thomas J. Herzfeld Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$90.94 - $199.54 $85,847 - $188,365	944 New	944 $85.8 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $3,119 - $3,453	20 Added 5.14%	409 $66,000
Q1 2023 May 16, 2023	SELL	$132.34 - $159.14 $21,703 - $26,098	-164 Reduced 29.66%	389 $61,000
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $19,279 - $25,442	-188 Reduced 25.37%	553 $74,000
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $2,858 - $3,507	30 Added 4.22%	741 $74,000
Q2 2022 Aug 10, 2022	SELL	$103.24 - $121.81 $22,299 - $26,310	-216 Reduced 23.3%	711 $79,000
Q1 2022 May 16, 2022	BUY	$93.1 - $112.54 $16,571 - $20,032	178 Added 23.77%	927 $103,000
Q4 2021 Feb 14, 2022	BUY	$95.88 - $117.08 $29,147 - $35,592	304 Added 68.31%	749 $84,000
Q3 2021 Nov 12, 2021	BUY	$84.42 - $106.62 $32,501 - $41,048	385 Added 641.67%	445 $43,000
Q2 2021 Aug 16, 2021	BUY	$67.66 - $84.76 $1,082 - $1,356	16 Added 36.36%	60 $5,000
Q3 2020 Nov 12, 2020	BUY	$63.69 - $70.22 $827 - $912	13 Added 41.94%	44 $3,000
Q2 2020 Aug 12, 2020	BUY	$58.54 - $67.94 $1,814 - $2,106	31 New	31 $2,000

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Thomas J. Herzfeld Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Thomas J. Herzfeld Advisors, Inc. with notifications on news.